secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001493152-24-018465
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Q1 revenue $10.3M (+4% YoY); income from ops $0.6M; record test volume +10%
--------------------------------------------------------------------------------

- Q1 net revenue $10.3M, up 4% YoY from $9.8M; test volume up 10% to record levels.
- Income from continuing ops $0.6M vs $0.4M prior year; operating income $0.9M vs $0.7M.
- Adjusted EBITDA $1.0M vs $1.2M prior year; gross margin 59% vs 61%.
- Cash collections $10.2M; cash balance $2.8M at Mar 31, 2024, down from $5.6M due to $3.1M debt paydown.
- Fifteenth consecutive quarter of YoY volume growth; CEO cites adoption of ThyGeNEXT, ThyraMIRv2, PancraGEN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315224018465/0001493152-24-018465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315224018465/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer